Angiolab, Inc. (XKON:251280)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,295.00
-5.00 (-0.12%)
At close: Jul 4, 2025, 3:30 PM KST
-39.08%
Market Cap 14.09B
Revenue n/a
Net Income n/a
Shares Out 3.28M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 381
Average Volume 1,178
Open 4,005.00
Previous Close 4,300.00
Day's Range 3,800.00 - 4,300.00
52-Week Range 3,715.00 - 9,200.00
Beta 0.14
RSI 39.59
Earnings Date n/a

About Angiolab

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis. Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity. In addition... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 251280
Full Company Profile

News

There is no news available yet.